It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Aims
A paucity of studies addressed sex‐related differences in clinical outcomes in the long term following acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI). In these patients, it remains uncertain whether heart failure (HF) might exert a differential impact on the prognosis in the long term.
Methods
We queried a large‐scale database of ACS patients undergoing PCI. The primary endpoint was new‐onset HF. Secondary endpoints included mortality, myocardial infarction, re‐PCI and ischaemic stroke. Propensity score matching was generated to balance group characteristics. A total of 3334 patients after propensity score matching were analysed. Follow‐up was assessed at the 5 year term.
Results
At 5 year follow‐up, HF risk increased significantly in males versus females {17.9% vs. 14.8%, hazard ratio [HR] [95% confidence interval (CI)] = 1.22 [1.03–1.44], P = 0.02}. At 5 year follow‐up, mortality was significantly higher in the male cohort as compared with the female cohort [HR (95% CI) = 1.23 (1.02–1.47), P = 0.02]. On landmark analysis, differences in mortality emerged after the first year and were maintained thereafter. Ischaemic outcomes were comparable between cohorts.
Conclusions
Following ACS, males experienced a greater long‐term risk of developing new‐onset HF as compared with females. This difference remained consistent across all prespecified subgroups. Mortality was significantly higher in males. No differences were observed in ischaemic outcomes. New‐onset HF emerges as a primary contributor to long‐term gender disparities after ACS and a strong predictor of mortality in men with HF.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Clinical and Experimental Cardiology, Clinical and Interventional Cardiology, University of Sassari, Sassari, Italy, SIRIO MEDICINE Research Network, Sassari, Italy
2 Department of Cardiology, Republican Clinical Hospital, Baku, Azerbaijan, Department of Family Medicine, Azerbaijan Medical University, Baku, Azerbaijan
3 Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland
4 Clinical and Experimental Cardiology, Clinical and Interventional Cardiology, University of Sassari, Sassari, Italy
5 Department of Cardiology and Internal Medicine, Nicolaus Copernicus University, Bydgoszcz, Poland





